Status:
RECRUITING
Safely Reduce Cystoscopic Evaluations for Hematuria Patients
Lead Sponsor:
Erasmus Medical Center
Conditions:
Hematuria
Urothelial Neoplasm
Eligibility:
All Genders
Phase:
NA
Brief Summary
The SeARCH-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.
Detailed Description
Microscopic hematuria (MH) can be a sign of an underlying disease, including malignancy of the urinary tract, and is reason for referral to a urology clinic. The current standard diagnostic workup for...
Eligibility Criteria
Inclusion
- Microscopically confirmed microscopic hematuria of voided urine defined as ≥3 erythrocytes per high power field
- Male patients ≥40 years
- Female patients ≥50 years
Exclusion
- History of urothelial bladder- or urinary tract cancer
- Presence of macroscopic (visible) hematuria
- Woman who is or may be pregnant
Key Trial Info
Start Date :
May 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2027
Estimated Enrollment :
1100 Patients enrolled
Trial Details
Trial ID
NCT06026189
Start Date
May 31 2023
End Date
May 31 2027
Last Update
September 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SeARCH-trial Pijpers
Rotterdam, Netherlands, 3015GD